Topadur Pharma

News

8.9.22

TOPADUR has been selected as a TOP 100 Scale-up 2022 with unicorn potential

TOPADUR Pharma AG has been selected among Switzerland's most promising scale-ups in 2022. Huge thanks to everyone of our team, supporters, and partners believing in us along the way!

Please check out the link below.

‍

Download Document Dokument herunterladen https://www.top100startups.swiss/On-the-road-to-growth-Switzerlands-most-promising-scaleups-in-2022 https://www.top100startups.swiss/On-the-road-to-growth-Switzerlands-most-promising-scaleups-in-2022

27.10.20

News

Scientific Publication in Chimia

TOP-N53: A Clinical Drug Candidate for the Treatment of Non-healing Wounds.

9.11.22

News

Scientific Publication in Pharmaceutics

Topical Wound Treatment with a NO-Releasing PDE5 Inhibitor Formulation Enhances Blood Perfusion and Promotes Healing in Mice.

3.7.20

Press Release

Dr. Daniel L. Vasella new member of the Board of Directors

The shareholders of the company elected today Dr. Daniel L. Vasella, as new member to the Board of Directors.

TOPADUR has been selected as a TOP 100 Scale-up 2022 with unicorn potential

Scientific Publication in Chimia

Scientific Publication in Pharmaceutics

Dr. Daniel L. Vasella new member of the Board of Directors

About us

Approach

Disease Areas

Investors

Contact